Use of bevacizumab in a patient with Whipple’s disease: managing diagnostic uncertainty.

Autor: Tjandra, Douglas Peter, Brett, Andrew, Murugasu, Anand
Zdroj: BMJ Case Reports; Oct2023, Vol. 16 Issue 10, p1-5, 5p
Abstrakt: A man in his 30s with intellectual disability presented with 1month of diarrhoea, weight loss and dyspnoea. Investigations were hampered due to significant anxiety. Laboratory tests detected microcytic anaemia and hypoalbuminaemia. CT demonstrated a fat-containing infiltrate in the mediastinum, mesentery and axillae, and pulmonary ground-glass infiltrates. Biopsy of the axilla showed cystic lymphatic malformations involving adipose tissue and lymph nodes, leading to a provisional diagnosis of generalised lymphatic anomaly. Over the subsequent 4months, the patient’s respiratory status deteriorated, leading to type 1 respiratory failure necessitating intubation. After multidisciplinary discussion, a decision was made to trial bevacizumab, an anti-VEGF agent, with subsequent improvement in respiratory status. While intubated, gastroscopy was performed; duodenal biopsies revealed pathognomonic changes of Whipple’s disease, confirmed on PCR of duodenal and axillae biopsies. This was deemed the most likely unifying diagnosis; antibiotic treatment was commenced, bevacizumab was ceased, and the patient has remained well after 18 months. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index